overview of the navtemadlin trials (nct03662126)
Published 1 year ago • 61 plays • Length 6:17Download video MP4
Download video MP3
Similar videos
-
16:38
what do the navtemadlin trials mean for clinical practice?
-
47:42
clinical trial club: navtemadlin vs best available therapy in relapsed or refractory myelofibrosis
-
5:18
jakarta trials: does fedratinib provide a survival benefit in patients with mf?
-
5:56
eha2022: what are the recent advances in mpn?
-
5:33
an mpn expert defines clinical trial types
-
20:43
measuring disease modification in mpn clinical trials
-
3:37
advancing mpn research: how clinical trials work
-
5:56
can ruxolitinib replace hydroxyurea as a frontline therapy for pv?
-
58:03
overview of the who hematopoietic classification 2024-07-01
-
48:56
overview of immune system
-
3:40
pros and cons of ruxolitinib for the treatment of mpns
-
8:24
understanding common mpn clinical trial terms
-
0:56
the role of navtemadlin in the mpn treatment landscape
-
31:29
clinical trials as an mpn treatment option: what you should know
-
3:19
when would you switch a patient with myelofibrosis from ruxolitinib?
-
3:07
do we need new endpoints to assess spleen response in mpn?
-
1:04:42
a conversation with mpn specialists: a summary of clinical trials, drugs, and what they do
-
3:49
can jak2v617f vaf variations help predict clinical and survival outcomes?
-
2:46
what is the clinical value and potential of momelotinib for anemic patients with myelofibrosis?
-
49:25
cimpact-now update 7: advancing the molecular classification of ependymal tumors
-
3:52
myeloproliferative neoplasms defined: what are et, pv, and mf?
-
2:08
a study exploring sotatercept and ruxolitinib in mpn-associated myelofibrosis and anemia